Research. Advocacy. Support.

We advance ovarian cancer research while supporting women and their families.

Learn more about OCRFA

Register for OCRFA's Ovarian Cancer National Conference

Join us for an informative and transformative weekend of inspiration and hope, July 13-15 in Washington DC. Meet other survivors, patients and caregivers, hear from experts, and make lasting connections with others who have been touched by ovarian cancer.

Learn More and Register

Know Your Risks

About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.

Learn about your risks

Risk Factors

Many factors can increase or decrease a woman's risk of developing ovarian cancer.

Increases Risk

  • Family history of breast, ovarian or colon cancer
  • Genetic mutations like BRCA
  • Post-menopausal
  • Increased age

Decreases Risk

  • Pregnancy
  • Breastfeeding
  • Use of oral contraceptives

Know the Symptoms

  • Bloating
  • Difficulty Eating
  • Pelvic / Abdominal Pain
  • Urinary Frequency

If these symptoms occur for more than 2 weeks and these symptoms are new or unusual for you, see a gynecologist and ask about ovarian cancer. Research shows that seeing a gynecologic oncologist for surgery and treatment significantly improves outcomes.

Spring Advocacy Day

OCRFA and our amazing advocates brought #TealAction to Capitol Hill on March 6, highlighting the need for increased ovarian cancer research funding and support at the federal level. Together, we are the voice of the ovarian cancer community. Join us for our next Advocacy Day on July 16th!

Learn More About OCRFA Advocacy

Latest News

  • Denmark Study Shows Assisted Reproduction Does Not Increase Risk of Ovarian Cancer

    (July 12, 2018) A study involving 58,472 women between 1994 and 2015 concluded that assisted reproductive treatment, or ART, did not lead to an increased risk of ovarian cancer. Originally it was thought that the hormones used in ART would increase ovarian activity, which would in turn increase one’s risk of ovarian cancer. However, data… More

  • Research Updates from the 2018 American Society of Clinical Oncology Annual Meeting

    (July 2, 2018) Last month the American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, IL. Thirty nine thousand people from around the world attend to learn about the latest in cancer research. Ovarian cancer survivor and research advocate Annie Ellis attended the meeting and wrote a report highlighting some of the… More

  • FDA Approves Bevacizumab Paired with Chemotherapy After Surgery for Advanced Ovarian Cancer

    (June 29, 2018) Avastin, or bevacizumab, was recently approved by the FDA to be used first with chemotherapy, then by itself, after surgery. A phase III trial studied 1,873 women who had not had any prior treatments for stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma. Once the women had undergone… More


Upcoming Events